
BIOAGE ALERT: Bragar Eagel & Squire, P.C. Is Investigating Bioage Labs, Inc. On Behalf Of Long-Term Stockholders And Encourages Investors To Contact The Firm
According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.
Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
If you are a long-term stockholder of BioAge, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at ... , by telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn , X , and Facebook , and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X .
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
...


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- First Trust Financials Alphadex Becomes The Largest Shareholders Of Freedom Holding After Timur Turlov
- Reddio Mainnet Alpha Is Live The First GPU-Accelerated Parallel EVM For AI-Native Dapps
- Cooking.City Bringing Back Value Redistribution To Solana Fair Launches
- Everstake Brings Ethereum Experts Together To Explore Post-Pectra And Institutional Adoption
- Strengthening UK Ties: Complycontrol Becomes Associate Member Of UK Finance
- BTCC Exchange Reports Remarkable Q2 2025 Performance With $957 Billion Trading Volume
Comments
No comment